PTIX
Closed
Protagenic Therapeutics
3.54
-0.11 (-3.01%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 3.65
Day's Range: 3.52 - 3.65
Send
sign up or login to leave a comment!
When Written:
1.72
Protagenic Therapeutics is a biotechnology company that focuses on developing innovative treatments for neuropsychiatric disorders. The company's approach is based on the discovery of novel targets in the brain that regulate the balance of neurochemicals, such as serotonin, dopamine, and norepinephrine.
Protagenic's lead drug candidate, PT00114, is a small molecule that targets the 5-HT1A receptor, which is involved in regulating mood, anxiety, and stress. The company is also developing other drug candidates that target different neurochemical systems, including the dopamine and norepinephrine systems.
Protagenic is headquartered in New York City and was founded in 2013. The company has partnerships with academic institutions and research organizations to advance its drug development programs.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Protagenic's lead drug candidate, PT00114, is a small molecule that targets the 5-HT1A receptor, which is involved in regulating mood, anxiety, and stress. The company is also developing other drug candidates that target different neurochemical systems, including the dopamine and norepinephrine systems.
Protagenic is headquartered in New York City and was founded in 2013. The company has partnerships with academic institutions and research organizations to advance its drug development programs.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








